Fig. 1

CRISPRa screens identified Linc01056 as a regulator of sorafenib response in HCC cells. (a) Flowchart of CRISPRa screening on MHCC97L cells. (b) 7-day treatment of sorafenib significantly suppressed the proliferation ability of MHCC97L cells. (c) Violin plot of the normalized read count of the sequencing result. The average count of the sorafenib-treated group was slightly higher. (d) Volcano plot of the changes of expression of lncRNAs upon 7-day exposure of sorafenib in HCC cells. (e) Linc01056 was one of most downregulated lncRNA upon acquisition of sorafenib resistance in HCCs. The acquired sorafenib resistance MHCC97L cells were obtained by prolonged seven-day 5 µM sorafenib treatment. (f) In sorafenib-resistant HCC tumour cells, the expression of Linc01056 was potently suppressed. (g) HCC cells were exposed to 1-, 7- and 12-day sorafenib at the dose of 10µM, it was observed that 1-day treatment of sorafenib induced Linc01056 expression, while long-term treatment of sorafenib suppressed Linc01056 expression. (h) Cell viability of MHCC97L were measured against sorafenib treatment for wild-type or 1-day or 7-day treated cells. *p < 0.05, **p < 0.01, ***p < 0.001